Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$17.63 - $21.74 $12.5 Million - $15.5 Million
-711,492 Reduced 24.47%
2,196,009 $43.3 Million
Q4 2023

Feb 13, 2024

SELL
$14.37 - $19.07 $2.44 Million - $3.24 Million
-169,948 Reduced 5.52%
2,907,501 $51 Million
Q3 2023

Nov 14, 2023

SELL
$13.62 - $20.2 $4.1 Million - $6.07 Million
-300,715 Reduced 8.9%
3,077,449 $53.5 Million
Q2 2023

Aug 11, 2023

BUY
$10.44 - $16.48 $6.29 Million - $9.93 Million
602,528 Added 21.71%
3,378,164 $47.6 Million
Q1 2023

May 12, 2023

BUY
$10.7 - $15.79 $12.9 Million - $19 Million
1,206,133 Added 76.85%
2,775,636 $29.9 Million
Q4 2022

Feb 10, 2023

BUY
$11.42 - $17.05 $1.41 Million - $2.1 Million
123,396 Added 8.53%
1,569,503 $23.5 Million
Q3 2022

Nov 14, 2022

BUY
$9.76 - $13.41 $9 Million - $12.4 Million
922,579 Added 176.22%
1,446,107 $18.6 Million
Q2 2022

Aug 15, 2022

BUY
$7.6 - $11.41 $3.98 Million - $5.97 Million
523,528 New
523,528 $5.07 Million
Q4 2021

Feb 14, 2022

SELL
$10.39 - $15.15 $1.6 Million - $2.33 Million
-153,618 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$11.39 - $16.23 $1.75 Million - $2.49 Million
153,618 New
153,618 $1.75 Million

Others Institutions Holding KNSA

About Kiniksa Pharmaceuticals, Ltd.


  • Ticker KNSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,470,400
  • Market Cap $734M
  • Description
  • Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...
More about KNSA
Track This Portfolio

Track Rubric Capital Management LP Portfolio

Follow Rubric Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rubric Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rubric Capital Management LP with notifications on news.